# Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities

**Bill ID:** S1159BB
**Session:** 2023
**Sponsor:** James Skoufis
**Status:** In Assembly Committee
**PDF:** [S1159B PDF](https://legislation.nysenate.gov/pdf/bills/2023/S1159B)

## Summary

Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  1159--B
  Cal. No. 381
 
  2023-2024 Regular Sessions
 
  I N  S E N A T E
 
  January 10, 2023
  ___________
 
 Introduced  by  Sens.  SKOUFIS,  THOMAS,  WEBB -- read twice and ordered
  printed, and when printed to be committed to the Committee  on  Health
  --  recommitted  to  the Committee on Health in accordance with Senate
  Rule  6,  sec.  8  --  committee  discharged,  bill  amended,  ordered
  reprinted  as  amended  and  recommitted to said committee -- reported
  favorably from said committee, ordered to  first  and  second  report,
  ordered  to  a third reading, amended and ordered reprinted, retaining
  its place in the order of third reading
 
 AN ACT to amend the public health law, in relation to requiring  disclo-
  sure  of  information  concerning  non-invasive prenatal screening for
  chromosomal abnormalities
 
  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section  1.  The  public health law is amended by adding a new section
 2533 to read as follows:
  ยง 2533. DISCLOSURE OF  INFORMATION  CONCERNING  NON-INVASIVE  PRENATAL
 SCREENING  FOR  CHROMOSOMAL ABNORMALITIES.  1. FOR THE PURPOSES OF THIS
 SECTION, THE TERM "NON-INVASIVE PRENATAL SCREENING" SHALL MEAN ANY  NON-
 INVASIVE  PRENATAL  SCREENING  OR  CELL FREE FETAL DNA SCREENING USED TO
 ASCERTAIN WHETHER A FETUS IS AT  RISK  FOR  CERTAIN  CHROMOSOMAL  ABNOR-
 MALITIES.
  2.  NON-INVASIVE PRENATAL SCREENINGS SHALL BE ACCOMPANIED BY A WRITTEN
 NOTICE, PROVIDED BY THE ENTITY WHICH MANUFACTURED, SUPPLIED,  OR  OTHER-
 WISE CREATED SUCH  TEST  OR WHICH  ADVERTISED  PERFORMING THESE PRENATAL
 SCREENING  TESTS, ABOUT THE USE OF SUCH TEST FOR SCREENING PURPOSES, THE
 FACT THAT NOT ALL HIGH RISK OCCURRENCES CORRESPOND TO A POSITIVE RESULT,
 THE FACT THAT NOT ALL LOW RISK RESULTS CORRESPOND TO A NEGATIVE  RESULT,
 A  CLEAR  STATEMENT INDICATING THAT NON-INVASIVE PRENATAL SCREENINGS ARE
 INTENDED SOLELY FOR SCREENING PURPOSES TO ASSESS RISK OF POSSIBLE  FETAL
 GENETIC  ABNORMALITIES  AND  IS  NOT  INTENDED TO BE USED FOR DIAGNOSTIC
 PURPOSES TO DETERMINE WHETHER SUCH ABNORMALITIES ACTUALLY EXIST AND THAT
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD04085-04-4
 S. 1159--B  2
 
 ANY POSITIVE RESULT SHOULD BE FOLLOWED BY CONFIRMATORY DIAGNOSTIC  TEST-
 ING,  AND  THAT  ADDITIONAL  FOLLOW  UP IS RECOMMENDED FOR ALL HIGH RISK
 SCREENING.  SUCH WRITTEN NOTICE SHALL BE PROVIDED  TO  A  PATIENT  OR  A
 POTENTIAL  PARENT:  (A)  PRIOR  TO ANY PRENATAL TEST; (B) WITH SUCH TEST
 RESULTS; AND (C) WITH ANY MATERIALS PROVIDED BY THE  ENTITY  PROVIDING
 OR  FACILITATING  THE  PRENATAL  TESTING.  SUCH  WRITTEN NOTICE SHALL BE
 REVIEWED AND APPROVED BY THE DEPARTMENT. SUCH WRITTEN  NOTICE  SHALL  BE
 PLAINLY  WORDED AND PROMINENTLY DISPLAYED IN ANY MATERIAL PRESENTED TO A
 PATIENT OR A POTENTIAL PARENT ABOUT PRENATAL TESTING SERVICES.
  C. NOTHING CONTAINED IN THIS SECTION SHALL BE  CONSTRUED  TO  LIMIT  A
 HEALTH  CARE PRACTITIONER LICENSED, CERTIFIED, OR AUTHORIZED UNDER TITLE
 EIGHT OF THE EDUCATION LAW FROM RECOMMENDING  CERTAIN  PRENATAL  TESTING
 SERVICES  ACCORDING  TO  THE  PRACTITIONER'S  REASONABLE  AND GOOD FAITH
 PROFESSIONAL JUDGMENT BASED ON THE FACTS OF A PATIENT'S CASE.
  ยง 2. Section 266 of the public health law is amended by adding  a  new
 subdivision 7 to read as follows:
  7.  NON-INVASIVE  PRENATAL  TESTING.  IN  ADDITION  TO THE INFORMATION
 PROVIDED PURSUANT TO THIS SECTION, THE COMMISSIONER SHALL  ALSO  DEVELOP
 COMPREHENSIVE INFORMATIONAL MATERIALS REGARDING THE BENEFITS AND LIMITA-
 TIONS OF NON-INVASIVE PRENATAL TESTING, INCLUDING THE DIFFERENCE BETWEEN
 NON-INVASIVE  PRENATAL  TESTING  AND  PRENATAL  DIAGNOSTIC TESTING. SUCH
 INFORMATION SHALL BE POSTED ON THE WEBSITE IN  A  PRINTABLE  FORMAT,  IN
 MULTIPLE  LANGUAGES  IN ACCORDANCE WITH SECTION TWO HUNDRED TWO-A OF THE
 EXECUTIVE LAW TO ALLOW ALL GENERAL HOSPITALS, DIAGNOSTIC  AND  TREATMENT
 CENTERS,  OBSTETRICIANS,  PRIMARY  CARE  PROVIDERS,  MIDWIVES, AND OTHER
 HEALTH CARE PROGRAMS PROVIDING WOMEN'S WELLNESS SERVICES TO PROVIDE  THE
 INFORMATION TO THEIR PATIENTS AS PART OF THEIR PRENATAL CARE ACTIVITIES.
 THE INFORMATIONAL MATERIALS SHALL ALSO INCLUDE:
  (A)  THE CURRENT RECOMMENDATIONS ON NON-INVASIVE PRENATAL TESTING MADE
 BY THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS  (ACOG),  AND
 THE  SOCIETY  FOR  MATERNAL  FETAL MEDICINE, AND THE AMERICAN COLLEGE OF
 MEDICAL GENETICS AND GENOMICS (ACMG);
  (B) A STATEMENT INFORMING INDIVIDUALS THAT NON-INVASIVE PRENATAL TEST-
 ING IS USED FOR SCREENING PURPOSES TO DETERMINE THE POTENTIAL FOR POSSI-
 BLE FETAL GENETIC ABNORMALITIES AND IS NOT INTENDED TO DETERMINE WHETHER
 OR NOT SUCH ABNORMALITIES EXIST;
  (C) A STATEMENT INFORMING INDIVIDUALS THAT NON-INVASIVE PRENATAL TEST-
 ING CARRIES A RISK OF  FALSE-POSITIVE  RESULTS  AND  THAT  ANY  POSITIVE
 RESULT SHOULD BE FOLLOWED UP WITH PRENATAL DIAGNOSTIC TESTING; AND
  (D) A LIST OF THE NON-INVASIVE SCREENING TESTS THAT HAVE BEEN APPROVED
 OR  CLEARED  BY  THE FEDERAL FOOD AND DRUG ADMINISTRATION (FDA), THE NEW
 YORK STATE CLINICAL LABORATORY EVALUATION PROGRAM (CLEP), OR BOTH, AND A
 SUMMARY OF THE KNOWN PERFORMANCE CHARACTERISTICS  OF  THESE  TESTS  WHEN
 AVAILABLE.
  ยง 3. This act shall take effect on the one hundred eightieth day after
 it  shall have become a law. Effective immediately, the addition, amend-
 ment and/or repeal of any rule or regulation necessary for the implemen-
 tation of this act on its effective date are authorized to be  made  and
 completed on or before such effective date.